glp-1 drugs retatrutide Retatrutide, a GIP, and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Extreme Side Effects Followed Overdose

GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) deliver remarkable weight loss but create a critical nutritional challenge: maintaining adequate protein intake

On Wednesday, the Food and Drug Administration issued a warning, calling compounded GLP-1 medications "risky for patients." "FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 (glucagon-like peptide-1 (GLP-1) receptor agonists) drugs, including semaglutide and tirzepatide, as an option for weight loss," the FDA said

When retatrutide becomes commercially available, switching from Ozempic will likely be possible under medical supervision

Patients should be extremely cautious of any websites, social media advertisements, or online retailers claiming to sell GLP-1 patches